Spin-offs + Start-ups
At LMU Munich, innovation in medicine starts with deep curiosity, hard work and team spirit, leading to real-world solutions. Our students, postdocs and staff share a common goal: to turn pioneering discoveries into advances that improve human health.
We’re proud to support ideas that grow beyond research into sustainable ventures, such as the biotech spin-off Eisbach Bio, which seeks to transform cancer treatment with sustainable medicines, the translational m4 Award Sugar Switch, which flips the cellular switch on the production of fat, and the GO-Bio Initial Award ProP, which engineers precision proteins for therapy. Each demonstrates how novel scientific insights and an engineering mindset can create tangible benefits for society.
We welcome collaboration with industry, clinicians, and academic partners who share our passion for turning knowledge into innovation. Students and postdocs interested in entrepreneurship or want to build a sustainable business are especially encouraged to get in touch. We look forward to supporting your ideas.
To read more about our spin-offs and start-up projects:
Eisbach Bio GmbH
Targeting the Engines of Cancer
Eisbach Bio, a spin-off from LMU, develops precision cancer medicines that turn off tumor-specific molecular machines essential for DNA repair and survival. By selectively blocking the allosteric activation of our targets in cancer cells, Eisbach’s drugs spare healthy tissue. The company exemplifies how academic discovery evolves into a transformative, patient-focused biotech that generates sustainable medicines.
Contact: Prof. Dr. Andreas Ladurner and Dr. Adrian Schomburg; www.eisbach.bio
m4 Award SugarSwitch
Flipping the Metabolic Switch
SugarSwitch Therapeutics pioneers first-in-class small molecules that act as molecular switches for a newly discovered glucose-metabolite receptor. By controlling how the body converts sugar into fat, SugarSwitch aims to develop breakthrough treatments for obesity, type 2 diabetes, and fatty-liver disease. The project unites structural biology and drug design to transform metabolic health.
Contact: Prof. Dr. Andreas Ladurner; andreas.ladurner@bmc.med.lmu.de
GO-Bio Initial Award ProP
Precision Proteins for Diabetes Therapy
The ProP project develops innovative proproteins that act as dual activators and inhibitors of key factors regulating the synthesis of fats, enabling tissue-specific control of metabolism. This approach promises a holistic therapy for type 2 diabetes and fatty-liver disease, improving insulin sensitivity while preventing organ damage. The work and platform bridges protein engineering with mRNA-based therapeutics.
Contact: Dr. Maren Heimhalt; maren.heimhalt@bmc.med.lmu.de
